News Channels

01 Aug 2017 Homology Medicines Announces $83.5 Million Series B Financing to Advance Lead Development Candidate and AMEnDR™ In Vivo Gene Editing Technology
01 Aug 2017 Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects
01 Aug 2017 NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
01 Aug 2017 Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
01 Aug 2017 Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan
01 Aug 2017 Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease
01 Aug 2017 Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
01 Aug 2017 GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber’s Hereditary Optic Neuropathy
01 Aug 2017 Isogenica Announces New Licence Agreement with Takeda
01 Aug 2017 Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B
01 Aug 2017 CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
01 Aug 2017 Acalabrutinib granted Breakthrough Therapy Designation by US FDA for the treatment of patients with mantle cell lymphoma
31 Jul 2017 InVivo Therapeutics Announces Updates on the INSPIRE Study
31 Jul 2017 Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
31 Jul 2017 Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
31 Jul 2017 Indivior PLC Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder
31 Jul 2017 Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program
31 Jul 2017 CONTROL Trial Shows Statin Therapy Reversed LDL Increases to Below Baseline Levels in NASH Patients Treated with OCA
31 Jul 2017 Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis
31 Jul 2017 Pain Therapeutics Announces FDA Has Cleared an Investigational New Drug (IND) Application for PTI-125

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top